Paul B. Manning
Director at Liquidia; 10% owner at Taysha Gene Therapies; Director at Candel Therapeutics. Based in Charlottesville, Virginia.
- Rank
- 663rd of 14,644
- Companies held
- 4
- Largest holding
- LQDA, 55.6% of total
- Latest SEC filing
- Jun 16, 2026
What the $311M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Taysha Gene Therapies TSHA Common Stock | Through Paul B. Manning Revocable Trust | 14,723,948 | $3.77 | $55.5M | 17.8% | Form 4, May 30, 2025 |
| Liquidia LQDA Common Stock | Through Paul B. Manning Revocable Trust | 798,335 | $56.63 | $45.2M | 14.5% | Form 4, Jun 16, 2026 |
| Liquidia LQDA Common Stock | Through BKB Growth Investments, LLC | 716,311 | $56.63 | $40.6M | 13.0% | Form 4, Jun 16, 2026 |
| Liquidia LQDA Common Stock | Directly | 475,465 | $56.63 | $26.9M | 8.7% | Form 4, Jun 16, 2026 |
| Liquidia LQDA Common Stock | Through PBM Capital Finance, LLC | 435,674 | $56.63 | $24.7M | 7.9% | Form 4, Jun 16, 2026 |
| Liquidia LQDA Common Stock | Through PBM 2024 Grantor Retained Annuity Trust | 430,828 | $56.63 | $24.4M | 7.8% | Form 4, Sep 2, 2025 |
| Taysha Gene Therapies TSHA Common Stock | Through PBM 2025 Grantor Retained Annuity Trust | 4,000,000 | $3.77 | $15.1M | 4.8% | Form 4, May 30, 2025 |
| Candel Therapeutics CADL Common Stock | Through Paul B. Manning Revocable Trust | 2,763,527 | $5.13 | $14.2M | 4.6% | Form 4, Feb 23, 2026 |
| Verrica Pharmaceuticals VRCA Common Stock | Directly | 3,958,189 | $2.89 | $11.4M | 3.7% | Form 4, Nov 25, 2025 |
| Liquidia LQDA Common Stock | Through PD Joint Holdings, LLC | 198,413 | $56.63 | $11.2M | 3.6% | Form 4, Jun 16, 2026 |
| Taysha Gene Therapies TSHA Common Stock | Through BKB Growth Investments, LLC | 2,841,704 | $3.77 | $10.7M | 3.4% | Form 4, May 30, 2025 |
| Verrica Pharmaceuticals VRCA Common Stock | Through BKB Growth Investments, LLC | 3,348,372 | $2.89 | $9.7M | 3.1% | Form 4, Nov 25, 2025 |
| Candel Therapeutics CADL Common Stock | Directly | 1,681,000 | $5.13 | $8.6M | 2.8% | Form 4, Feb 23, 2026 |
| Candel Therapeutics CADL Common Stock | Through BKB Growth Investments, LLC | 1,303,752 | $5.13 | $6.7M | 2.1% | Form 4, Feb 23, 2026 |
| Taysha Gene Therapies TSHA Common Stock | Directly | 1,333,333 | $3.77 | $5.0M | 1.6% | Form 4, Jun 27, 2024 |
| Verrica Pharmaceuticals VRCA Common Stock | Through trust | 332,433 | $2.89 | $959K | 0.3% | Form 4, Nov 25, 2025 |
| Verrica Pharmaceuticals VRCA Common Stock | Through trust | 89,187 | $2.89 | $257K | 0.1% | Form 4, Nov 25, 2025 |
| Taysha Gene Therapies TSHA Common Stock | Through BKB G2 Investments, LLC | 22,000 | $3.77 | $83K | 0.0% | Form 4, May 30, 2025 |
| Verrica Pharmaceuticals VRCA Common Stock | Through PBM Capital Investments, LLC | 25,663 | $2.89 | $74K | 0.0% | Form 4, Nov 25, 2025 |
Share counts are the amounts Paul B. Manning reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Sold | LQDA | 19,125 | $62.62 | $1.2M | View |
| Jun 4, 2026 | Sold | LQDA | 68,265 | $63.83 | $4.4M | View |
| Jun 4, 2026 | Sold | LQDA | 88,487 | $64.28 | $5.7M | View |
| Jun 4, 2026 | Sold | LQDA | 11,513 | $63.13 | $727K | View |
| Jun 4, 2026 | Sold | LQDA | 12,610 | $64.42 | $812K | View |
| Feb 23, 2026 | Bought | CADL | 550,458 | $5.45 | $3.0M | View |
| Nov 25, 2025 | Bought | VRCA | 1,375,380 | $4.24 | $5.8M | View |
| Nov 25, 2025 | Bought | VRCA | 2,750,762 | $4.24 | $11.7M | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 660 | Tunc Doluca Director, Analog Devices. San Jose, CA | $315M |
| 661 | Christina Tan Director, Pangaea Logistics Solutions. Stamford, CT | $314M |
| 662 | Charles H. Giancarlo CEO, Everpure. Santa Clara, CA | $314M |
| 663 | Paul B. Manning Director, Liquidia. Charlottesville, VA | $311M |
| 664 | David Nanus 10% owner, NRG Energy. New York, NY | $310M |
| 665 | Richard B. Leeds Executive Chairman, Global Industrial. Port Washington, NY | $309M |
| 666 | Michael K. Lester President and CEO, LifeStance Health Group. Scottsdale, AZ | $309M |
Other Liquidia insiders
All LQDA insiders- Roger Jeffs$125MChief Executive Officer. #1208 overall
- Russell Schundler$35.5MSee Remarks. #3286 overall
- Michael Kaseta$19.3MCFO and COO. #5351 overall
- Robert A. Lippe$11.0MChief Operations Officer. #8172 overall
- Scott Moomaw$10.3MChief Commercial Officer. #8609 overall
- Jason Adair$10.0MChief Business Officer. #8761 overall
Questions
How much stock does Paul B. Manning own?
Paul B. Manning holds $311,276,747 in listed stock based on SEC filings and current prices, mostly Taysha Gene Therapies (TSHA). That ranks 663rd on the Stock Rich List.
Is this Paul B. Manning's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Paul B. Manning last buy or sell stock?
The most recent open-market trade on file is a sale of 19,125 LQDA shares on Jun 4, 2026 at $62.62.